Philip van Damme studied neurology at KU Leuven medical school. During his neurology training, he did a PhD on disease mechanisms of ALS, and continued to work on this disease after graduating in 2006. In 2008 he was a visiting neuromuscular fellow at the MGH, Boston and visiting researcher at the Day Laboratory for Neuromuscular Research, Harvard Medical School in Boston. Since 2009, he has been appointed as neuromuscular specialist at the neurology department in UZ Leuven and as professor at the department of Neuroscience at KU Leuven. He is leading the ALS program that involves the diagnosis, treatment and multidisciplinary care for patients with ALS. He is actively involved in clinical research, including genetic, biomarker and neuroimaging studies and clinical trials with new treatments for ALS. He currently is the chair of the EAN guideline panel on ALS.
He also is a principal investigator in the laboratory for Neurobiology (part of the Neuroscience Department at the University of Leuven and the VIB Center for Brain & Disease Research). His current research focuses on genetic modifiers of ALS and on disease pathways in pluripotent stem cell models derived from ALS patients. Philip Van Damme published more than 200 papers in international peer-reviewed journals on ALS and related neuromuscular disorders.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.